Intervention in gastro-enteropancreatic neuroendocrine tumours

Détails

ID Serval
serval:BIB_3E5584420911
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Intervention in gastro-enteropancreatic neuroendocrine tumours
Périodique
Best Pract Res Clin Gastroenterol
Auteur(s)
Baudin E., Planchard D., Scoazec J. Y., Guigay J., Dromain C., Hadoux J., Debaere T., Elias D., Ducreux M.
ISSN-L
1532-1916 (Electronic)1521-6918 (Linking)
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
26
Numéro
6
Pages
855-65
Langue
anglais
Notes
Baudin, EricPlanchard, DavidScoazec, Jean-YvesGuigay, JoelDromain, ClarisseHadoux, JulienDebaere, ThierryElias, DominiqueDucreux, MichelengReviewNetherlands2013/04/16 06:00Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):855-65. doi: 10.1016/j.bpg.2013.01.008.
Résumé
Neuroendocrine tumours require dedicated interventions to control their capacity to secrete hormones but also, antitumour growth strategies. Recommendations for early interventions in NET include the management of hormone-related symptoms and poorly differentiated neuroendocrine carcinomas. In contrast, prognostic heterogeneity is a key feature of well differentiated NET that complexified the antitumour strategy whatever the stage in this subgroup of tumour. In this review, timely therapeutic interventions to control hormone-related symptoms and tumour growth in GEP NET patients are discussed. The necessity of controlling hormone-related symptoms as the first step of any strategy affects also the tumour growth control strategy. In the absence of cure at the metastatic stage, progresses are expected in the recognition of well differentiated NET subgroups that display either excellent or poor prognosis.
Mots-clé
Antineoplastic Agents, Hormonal/*therapeutic use, Bronchial Neoplasms/complications/metabolism/mortality/pathology/*therapy, Carcinoid Tumor/complications/metabolism/mortality/pathology/*therapy, Humans, Intestinal Neoplasms/complications/metabolism/mortality/pathology/*therapy, Neuroendocrine Tumors/complications/metabolism/mortality/pathology/*therapy, Pancreatic Neoplasms/complications/metabolism/mortality/pathology/*therapy, Prognosis, Randomized Controlled Trials as Topic, Stomach Neoplasms/complications/metabolism/mortality/pathology/*therapy
Création de la notice
16/09/2016 10:14
Dernière modification de la notice
20/08/2019 13:35
Données d'usage